Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT04837131 · Michael M. Pham · PHASE2 · terminated · last registry update 2025-04-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low enrollment” | – | Registry record, Michael M. Pham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PSMD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-20Results posted on the registry: Celgene, CC-220 + Dexamethasone (NCT02773030)
- 2026-03-06Results posted on the registry: University of Colorado, Denver, Selinexor + Pomalidomide (NCT04925193)
- 2026-03-05Results posted on the registry: University of Washington, Ixazomib Citrate + Rituximab (NCT02339922)
- 2026-02-10Results posted on the registry: National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2026-02-10Also stopped (terminated): National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2026-02-06Phase 3 first posted: AstraZeneca, AZD0120 + Daratumumab (NCT07391657)
- 2026-01-29Also stopped (terminated): Teva Branded Pharmaceutical Products R&D LLC, Modakafusp alfa + Lenalidomide (NCT05556616)
- 2026-01-22Results posted on the registry: University of Chicago, Ixazomib Citrate + Lenalidomide (NCT02389517)
- 2026-01-05Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2025-11-20Results posted on the registry: Memorial Sloan Kettering Cancer Center, Carfilzomib + Lenalidomide (NCT02937571)
- 2025-10-30Phase 3 first posted: Regeneron Pharmaceuticals, Linvoseltamab + Carfilzomib (NCT07222761)
- 2025-10-21Also stopped (terminated): University of California, San Diego, Ixazomib + Pomalidomide (NCT03590652)
- 2025-10-07Also stopped (terminated): University of Pennsylvania, Tasquinimod + IRd chemotherapy (NCT04405167)
- 2025-09-18Results posted on the registry: Mayo Clinic, Ibrutinib + Ixazomib Citrate (NCT03506373)
- 2025-09-10Results posted on the registry: University of Chicago, Elotuzumab + Carfilzomib (NCT02969837)
- 2025-09-02Also stopped (terminated): Millennium Pharmaceuticals, Inc., IXAZOMIB + Dexamethasone (NCT01659658)
- 2025-08-06Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, Modakafusp alfa + Lenalidomide (NCT05556616)
- 2025-06-26Results posted on the registry: Emory University, Dexamethasone + Ixazomib (NCT02765854)
- 2025-06-17Results posted on the registry: Therapeutic Advances in Childhood Leukemia Consortium, Ixazomib + Vincristine (NCT03817320)
- 2025-06-04Results posted on the registry: Mayo Clinic, Daratumumab + Dexamethasone (NCT03012880)
- 2025-06-04Results posted on the registry: Amgen, Carfilzomib + Dexamethasone (NCT02303821)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-05-02Results posted on the registry: Gilead Sciences, Magrolimab + Daratumumab (NCT04892446)
- 2025-05-02Also stopped (terminated): Gilead Sciences, Magrolimab + Daratumumab (NCT04892446)
- 2025-04-20Also stopped (terminated): M.D. Anderson Cancer Center, Ixazomib + Ixazomib Citrate (NCT04047797)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision